newsfilter
← Earnings
Earnings Releases·

Acrivon Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $17.9 million for Q3 2026 from $18.2 million in the prior year period, driven by a $2.0 million reduction in general and administrative expenses, while R&D costs rose to $14.5 million due to clinical trial timing for ACR-368 and ACR-2316; cash reserves of $77.8 million are sufficient to fund operations through Q4 2027.
  • Strategic expansion into Immunology and Inflammation (I&I) was solidified with the acquisition of ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a preclinical PKCθ program, positioning I&I as a second pillar alongside the oncology portfolio.
  • Key clinical milestones include expected Phase 2b interim analysis and complete enrollment for ACR-368 in serous endometrial cancer by Q4 2026, ACR-2316 dose expansion completion by mid-2027, and an IND filing for ACR-7280 targeted for H1 2027.
  • Management highlighted transformative progress with ACR-2316 demonstrating long-lasting clinical benefit and confirmed responses in heavily pretreated lung and endometrial cancers, alongside favorable safety data for ACR-525 in Phase 1 studies.
Company
ACRIVON THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology